Skip to main content
logo
Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
19.49
+1.08 (5.87%)
At close: Jul 27, 2026, 4:00 PM EDT
19.60
+0.11 (0.56%)
After-hours: Jul 27, 2026, 7:34 PM EDT

Amylyx Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-307.12-301.74-144.7449.27-198.38-87.93
Depreciation & Amortization
0.470.530.91.090.490.05
Stock-Based Compensation
26.9327.6533.0437.1621.713.14
Other Adjustments
-0.55-5.7145.99-9.94-2.065.35
Change in Receivables
-0.3639.6-74.74-15.31-
Changes in Inventories
-5.96-9.25-73.13-9.77-
Changes in Accounts Payable
-1.280.58-19.115.881.850.67
Changes in Accrued Expenses
-1.39-6.6-59.8121.626.058.43
Changes in Other Operating Activities
2.290.912.17-5.27-4.47-4.51
Operating Cash Flow
-120.4-123.34-167.6511.92-179.87-74.8
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.13-0.14-0.16-1.24-2.53-0.35
Purchases of Intangible Assets
-4--36.2---
Purchases of Investments
-147.91-231.82-231.99-300.83-415.87-49.05
Proceeds from Sale of Investments
246246344394.12179.413
Investing Cash Flow
93.9614.0475.6592.05-238.99-46.41

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-----26.16
Net Long-Term Debt Issued (Repaid)
-----26.16
Issuance of Common Stock
10.274.082.136.99434.640.34
Net Common Stock Issued (Repurchased)
10.274.082.136.99434.640.34
Issuance of Preferred Stock
-----135
Net Preferred Stock Issued (Repurchased)
-----135
Other Financing Activities
184.32252.95-1.78-3.45-2.85-3
Financing Cash Flow
194.58257.030.353.54431.79158.51

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.771.07-0.440.16-0.070.01
Net Cash Flow
168.91148.8-92.08107.6812.8737.31

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-120.53-123.48-167.810.68-182.4-75.15
Free Cash Flow Growth
------
FCF Margin
---192.06%2.80%-820.50%-26369.10%
Free Cash Flow Per Share
-1.20-1.31-2.460.15-3.12-11.41
Levered Free Cash Flow
-75.87-143.5-386.998.2-186.75-57.48
Unlevered Free Cash Flow
-78.92-152.11-399.57-5.86-190.5-78.39
SEC Filings: 10-K · 10-Q